Trial Profile
A Phase I Trial of Pomalidomide for Children With Recurrent, Progressive or Refractory CNS Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Apr 2022
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary)
- Indications CNS cancer; Nervous system neoplasms
- Focus Adverse reactions; Pharmacokinetics
- 22 Apr 2022 Status changed from active, no longer recruiting to completed.
- 13 Apr 2018 Planned primary completion date changed from 31 Mar 2018 to 31 Mar 2020.
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.